Doxorubicin (as part of multi-agent chemotherapy)

Treatment for Hepatoblastoma

Typical Dosage: Various regimens, e.g., 30-60 mg/m2 per cycle

Effectiveness
75%
Safety Score
25%
Clinical Trials
200
Participants
10K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Various regimens, e.g., 30-60 mg/m2 per cycle
Time to Effect
weeks
Treatment Duration
Part of a 4-6 month regimen
Evidence Quality
HIGH
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,000
Monitoring:$5,000
Side Effect Mgmt:$10,000
Total Annual:$17,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
QALYs Gained
15
Outcome-Based Costs
Cost per Responder
$24,285.71
Cost per Remission
$24,285.71
Doxorubicin (as part of multi-agent chemotherapy) Outcomes

for Hepatoblastoma

Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+70%
Remission Rate
+70%
Common Side Effects
Myelosuppression
+85%
Nausea and vomiting
+80%
Hair loss
+95%
Cardiotoxicity (cumulative dose)
+20%
Mucositis
+50%

Sources:

northwestern.edu
nih.gov
ascopubs.org

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov